Tirzepatide may have direct protective effects on various tissues that play a role in MASLD pathology.40,41 Furthermore, glucagon and GIP have direct effects on hepatic fatty acid β-oxidation and lipogenesis, contributing to decreased LFC. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.